OTCMTNBI
Market cap508kUSD
Dec 23, Last price
0.02USD
1D
16.50%
1Q
86.40%
IPO
-97.69%
Name
Tanke Biosciences Corp
Chart & Performance
Profile
Tanke Biosciences Corporation, through its subsidiaries, develops, produces, markets, and sells animal nutrition and feed additive products. It operates in four segments: Organic Trace Mineral Additives, Functional Regulation Additives, Herbal Medicinal Additives, and Other. The company offers organic trace mineral additives under the Qili brand name; feed acidifiers, which are used to prevent microbial degradation of raw materials or finished feeds under the Qilicid name; seasonings; flavor enhancers that are used as the agent in the production of blended feed under the Tankeball name; and herbal medicinal additives blended with feed products under the Extra-Health, Qilimix, and Recoccider names. It also produces and markets multiple trace mineral premix products for livestock and poultry under the Qilimix name. In addition, the company provides natural sweeteners and attractants for use with feed for pigs, piglets, fish, and other aquatic animals under the Tankeball name; and water soluble organic multi-vitamin electrolyte, which is fed to animals through dissolving it in drinking water for the animals to consume. It serves mid-to-large sized feed product factories, large scale feed producers, and farmers. The company sells its products primarily in the People's Republic of China, Southeast Asia, and Latin America. Tanke Biosciences Corporation was founded in 1989 and is headquartered in Guangzhou, the People's Republic of China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | |||||
Cost of revenue | 8 | 256 | 1,335 | ||
Unusual Expense (Income) | |||||
NOPBT | (8) | (256) | (1,335) | ||
NOPBT Margin | |||||
Operating Taxes | (83) | ||||
Tax Rate | |||||
NOPAT | 74 | (256) | (1,335) | ||
Net income | (83) -15.92% | (98) -86.42% | (723) | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
Debt | |||||
Debt current | 140 | 53 | 2 | ||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | 137 | 46 | (40) | ||
Cash flow | |||||
Cash from operating activities | (75) | (59) | (4) | ||
CAPEX | 2 | ||||
Cash from investing activities | |||||
Cash from financing activities | 70 | 25 | 45 | ||
FCF | 19 | (279) | (1,277) | ||
Balance | |||||
Cash | 3 | 7 | 41 | ||
Long term investments | |||||
Excess cash | 3 | 7 | 41 | ||
Stockholders' equity | (13,116) | (13,034) | (12,952) | ||
Invested Capital | 13,160 | 12,999 | 12,893 | ||
ROIC | 0.57% | ||||
ROCE | 729.84% | 2,294.92% | |||
EV | |||||
Common stock shares outstanding | 21,113 | 12,476 | 12,746 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (256) | (1,335) | |||
EV/EBITDA | |||||
Interest | 56 | 56 | 2 | ||
Interest/NOPBT |